Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EffCaMgCit in CKD Stage V
NCT03565913Phase 3Active, not recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Jan 2017
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in chronic kidney disease (CKD) (2 arms), sponsored by UT Southwestern Medical Center. Primary endpoint: Serum T50 for CPP at 24 months. Started Jan 2017; status: active, not recruiting.
02
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT03565913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03565913.